DeepWork Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells.
BiotechHealthtechMedical DevicesWoburn, US
Shelley A. Hartman(Co-founder & CEO)inEvangelos V. Badiavas(Founder & Chief Scientific Officer)Heidi Kempinski(Chief Operational Officer)inKathleen Murphy(Head of Clinical Operations)Robert Williamson, Jr.(Executive Officer, Director)Robert Ryan(Director)
Co-investorsDEFTA PartnersNew World AngelsOcean Azul Partners
Eternatear develops diagnostic and therapeutic products for dry eye disease, particularly targeting Meibomian Gland Dysfunction.
BiotechHealthtechMedical DevicesRaleigh, US
Timothy Willis(Chief Executive Officer & Chairman of the Board)Kent Geer(Chief Financial Officer & Secretary)Tim Willis(CEO, Chairman of the Board)Ralph Stone(Chief Technology Officer)Joe Huber(Chief Operating Officer)Diethart Reichardt(Chief Marketing Officer & Board Director)
Co-investorsArieal Southeast Angel PartnersCharlotte Angel FundDuke Capital PartnersKleinmuntz AssociatesBand of AngelsCarolina Angel Network+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.











